ReviewApplied microbiology and biotechnology2022
Microbial L-asparaginase as a promising enzyme for treatment of various cancers.
Review in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Fungal L-Asparaginase from environmental isolates with antimicrobial and antibiofilm activities.AMB Express · 2026Article
- Microbial-Derived Anti-Cancer Compounds: Advances in Drug Discovery, Bioengineering, and Therapeutic Applications.Anti-cancer agents in medicinal chemistry · 2026Review
- Autophagy-targeted intervention synergized with pegaspargase: an innovative therapeutic paradigm for pancreatic cancer.Cancer cell international · 2025Article
- Secretory Expression ofJournal of microbiology and biotechnology · 2025Article
- L-asparaginase: a review of microbial production and protein engineering with translational applications for oncology and food safety.World journal of microbiology & biotechnology · 2025Review
- Enhanced production of extracellular L-asparaginase in batch culture via nitrous acid-induced mutagenesis of Aspergillus oryzae.Microbial cell factories · 2025Article
- Marine-derived L-asparaginase: unlocking marine power in anti-tumor therapeutics.Frontiers in immunology · 2025Review
- Article
- Phylogenetic affiliation of endophytic actinobacteria associated with red gum tree grown in salinity area and their plant growth promoting properties and suppression of phytopathogens, and genome data mining of selected strains.Frontiers in plant science · 2025Article
- Substrate Affinity Is Not Crucial for Therapeutic L-Asparaginases: Antileukemic Activity of Novel Bacterial Enzymes.Molecules (Basel, Switzerland) · 2024Article
- Cloning, expression, and characterization of a novel thermo-acidophilic l-asparaginase of3 Biotech · 2024Article
- Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production.International journal of molecular sciences · 2023Review
- l-Asparaginase Type II fromPharmaceutics · 2023Article
- Endophytic Fungi as a Promising Source of Anticancer L-Asparaginase: A Review.Current microbiology · 2023Review
- l-Asparaginase producing novel3 Biotech · 2023Article
- Asparagine and Glutamine Deprivation Alters Ionizing Radiation Response, Migration and Adhesion of a p53International journal of molecular sciences · 2023Article
- Extracellular L-Asparaginase SynthesisAvicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic differences between normal and cancerous cells have been used as a point of view for developing anticancer drugs. Some degrading enzymes of certain amino acids have been regarded to kill cancerous cells. L-Asparaginase (ASNase) has shown an excellent therapeutic response to asparagine-auxotrophic cancers such as acute lymphoblastic leukemia (ALL). Some bacteria, yeasts, molds, plants, and animals produce ASNase. Bacterial ASNases from Escherichia coli and Erwinia chrysanthemi are the FDA-approved drugs for ALL treatment. Here, we review new natural prokaryotic and eukaryotic sources of ASNases, recent advances to introduce improvement strategies for the production of recombinant ASNases as well as their chemical modifications, immobilization, nanoencapsulation, and in silico studies to increase efficiency and decrease side effects. Recent studies for application of ASNases to treatment of asparagine-auxotrophic cancers, especially solid cancers, have been reviewed. Furthermore, challenges and future perspectives are discussed for this promising therapeutic enzyme. KEY POINTS: • Review recent advances to introduce new sources of microbial L-asparaginases. • Review improvement strategies for the development of stable and non-toxic L-asparaginases. • Review microbial L-asparaginase application in various cancers' treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.